This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer (Macrobead)

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by The Rogosin Institute
Sponsor:
Information provided by (Responsible Party):
The Rogosin Institute
ClinicalTrials.gov Identifier:
NCT01053013
First received: January 20, 2010
Last updated: May 3, 2017
Last verified: May 2017
  Purpose

This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer responds to standard therapies.

The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress.


Condition Intervention Phase
Pancreatic Cancer Colorectal Cancer Biological: Cancer macrobead placement in abdominal cavity Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by The Rogosin Institute:

Primary Outcome Measures:
  • Tumor volume and number of metastases [ Time Frame: 16 months ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: 16 months ]

Estimated Enrollment: 60
Study Start Date: February 2010
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cancer macrobeads
Cancer macrobead placement in abdominal cavity
Biological: Cancer macrobead placement in abdominal cavity
8 macrobeads per kilogram
Other Name: cancer macrobeads

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cancer of pancreas, colon or rectum
  • Evidence of metastasis
  • Failed available therapies (pancreatic cancer may be treated without previous therapies)
  • Resolution of any toxic effects of previous therapies
  • Performance status (ECOG PS) 0-2
  • Adequate hematologic, coagulation (INR 2-3 max), hepatic and renal function
  • Life expectancy of at least 6 weeks
  • For females, a negative pregnancy test
  • Agrees to contraceptive use while on study if sexually active
  • Informed consent

Exclusion Criteria:

  • Any condition presenting an unacceptably high anesthetic or surgical risk
  • HIV positive
  • Cognitive impairment such as to preclude informed consent
  • Surgical treatment or chemotherapy within three weeks of scheduled macrobead implantation or within four weeks of bevacizumab (or similar drugs), or radiation therapy within four weeks of scheduled macrobead implantation
  • Inadequate hematologic, coagulation (INR >3), hepatic, renal function
  • Hepatic blood flow abnormalities and/or large-volume ascites
  • Concurrent cancer of any other type except skin cancer (excluding melanoma)
  • History of allergic reactions to mouse antigens
  • Active infection, congestive heart failure, unstable angina, serious cardiac arrhythmias, psychiatric illness, difficult social situations not permitting reliable participation, active bleeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01053013

Contacts
Contact: Barry H Smith, MD, PhD 212-746-1551 bas2005@nyp.org
Contact: Nathaniel Berman, MD 212-746-9766 nab2009@nyp.org

Locations
United States, New York
Weill Cornell Medical College/The Rogosin Institute Recruiting
New York, New York, United States, 10021
Contact: Angelica Nazarian    212-746-9233    macrobead@nyp.org   
Contact: Nathaniel Berman, MD    212-746-9766    nab2009@nyp.org   
Principal Investigator: Thomas J. Fahey, M.D.         
Sub-Investigator: Nathaniel Berman, M.D.         
Sub-Investigator: Allyson Ocean, M.D.         
Sub-Investigator: Barry H. Smith, M.D., Ph.D.         
Sponsors and Collaborators
The Rogosin Institute
Investigators
Study Director: Barry H Smith, MD, PhD The Rogosin Institute
  More Information

Additional Information:
Responsible Party: The Rogosin Institute
ClinicalTrials.gov Identifier: NCT01053013     History of Changes
Other Study ID Numbers: 0911010739
Study First Received: January 20, 2010
Last Updated: May 3, 2017

Keywords provided by The Rogosin Institute:
macrobead
biological
mouse cells

Additional relevant MeSH terms:
Colorectal Neoplasms
Pancreatic Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on June 23, 2017